{"prompt": "['B. Braun Medical Inc.', 'OPM-G-H-1506', 'Prontosan', 'Protocol Amendment 2', '14 REFERENCES', '1.', 'Richmond NA, Maderal AD, Vivas AC. Evidence-based management of common', 'chronic lower extremity ulcers. Dermatol Ther. 2013;26:187-196.', '2.', 'Canadian Agency for Drugs and Technologies in Health. Optimal care of chronic,', 'non-healing, lower extremity wounds: a review of clinical evidence and guidelines.', 'Ottawa, ON, Canada, 2013.', '3.', 'Frykberg RG and Banks J. Challenges in the treatment of chronic wounds. Adv', 'Wound Care. 2015;4(9):560-582.', '4.', 'McCarty SM and Percival SL. Proteases and delayed wound healing. Adv Wound', 'Care. 2013;2:438-447.', '5.', 'Leaper DJ, Schultz G, Carville K, et al. Extending the TIME concept: what have we', 'learned in the past 10 years? Int Wound J. 2012;9(2): 1-19.', '6.', 'Romanelli M, Dini V, Barbanera S, et al. Evaluation of the efficacy and tolerability of', 'a solution containing propyl betaine and polihexanide for wound irrigation. Skin', 'Pharmacol Physiol. 2010;23(1):41-44.', '7.', 'FDA letter of issuing substantial equivalence (for prescription use): 501(k) K072876', '(Prontosan Wound Irrigation Solution), dated 19 June 2008.', '8.', 'FDA letter of issuing substantial equivalence (for over-the-counter use): 501(k)', 'K110744 (Prontosan Wound Irrigation Solution), dated 06 April 2011.', '9.', 'Prontosan Wound Irrigation Solution Instructions for Use, 350-mL bottle, B. Braun', 'Medical Inc., revised April 2011.', '10.', 'Prontosan Wound Gel Instructions for Use, 30-mL bottle, B. Braun Medical Inc.,', 'revised January 2011.', '11.', 'Andriessen AE and Eberlein TE. Assessment of a wound cleansing solution in the', 'treatment of problem wounds. Wounds. 2008;20(6):171-175.', '12.', 'Moeller A, Nolte A, Kaehn K. Experiences in using polihexanide containing wound', 'products in the management of chronic wounds-results of a methodical and', '14 November 2018', 'Page 51']['B. Braun Medical Inc.', 'OPM-G-H-1506', 'Prontosan', 'Protocol Amendment 2', 'retrospective analysis of 953 cases. Wundmanagement. 2008;3:112-117.', '13.', 'Price P and Krasner DL. Health-related quality of life and chronic wounds: evidence', 'and implications for Practice. In Krasner DL, Rodeheaver GT, Sibbald RG, Woo KY,', 'eds., Chronic Wound Care: The Essentials; A Clinical Source Book for Healthcare', 'Professionals. Vol. 1, 5th edition, Malvern, PA, HMP Communications, 2014.', '14.', 'Blome C, Baade K, Debus ES, et al. The Wound-QoL: a short questionnaire', 'measuring quality of life in patients with chronic wounds based on three established', 'disease-specific instruments. Wound Repair Regen. 2014;22(4):504-514.', '15.', 'Augustin M, Baade K, Herberger K, et al. Use of the Wound-QoL instrument in', 'routine practice: feasibility, validity, and development of an implementation tool.', 'Wound Medicine. 2014;5:4-8.', '16.', 'Wound-QoL Short Manual, dated September 2015. Available on http://www.wound-', 'qol.com, accessed on 29 March 2016.', '17.', 'Morgan N. Measuring wounds. Wound Care Advisor. Available on', 'ittp://woundcareadvisor.com/measuring-wounds, published 11 July 2012.', '18.', 'FDA letter of issuing substantial equivalence (for prescription use): 501( (k) K090141', '(Prontosan Wound Gel), dated 17 March 2009.', '19.', 'FDA letter of issuing substantial equivalence (for over-the-counter use): 501(k)', 'K101882 (Prontosan Wound Gel), dated 03 November 2010.', '20.', 'Burckhardt CS and Jones KD. Adult measures of pain. Arthritis & Rheumatism.', '2003;49(5S):S96-S104.', '21.', 'Kalinski C, Schnepf M, Laboy D, et al. Effectiveness of a topical formulation', 'containing metronidazole for wound odor and exudate control. Wounds.', '2005;17(4):84-90.', '14 November 2018', 'Page 52']\n\n###\n\n", "completion": "END"}